Document Detail


Treatment of haemophilia A in Tunisia: efficacy and inhibitor study.
MedLine Citation:
PMID:  12923586     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Cryoprecipitate is the principal type of factor VIII (FVIII) concentrate used for treating haemophilia A in Tunisia. Allergic reactions, viral transmission, and inhibitor formation remain the most serious complications of FVIII therapy. The aims of the study presented here were to evaluate the efficacy of FVIII therapy, to investigate the inhibitor prevalence, and the factors which may affect inhibitor formation in our haemophilia A patients. Plasma samples were screened for FVIII inhibitors by the Bethesda method. 30 minutes FVIII recovery was also determined for each patient. In this prospective study, 18 previously treated haemophilia A patients, four with severe (FVIII concentration <2%) and 14 with moderate haemophilia, were closely followed up during administration of 223 FVIII concentrates (cryoprecipitate and/or fresh frozen plasma). The median age of the patients involved in the study was 13.5 years (range 5 to 53). Clinical response to FVIII was consistently good to excellent. In the majority of cases, actual and predicted FVIII recovery correlated' well. Adverse reactions were not observed. Five patients, aged less than 18 years and minimally treated (>36 FVIII exposure days), were found to have low titre FVIII inhibitors (<10 Bethesda units) at the end of the study. Inhibitor activity was detected in one patient with severe and in four patients with moderate haemophilia. In conclusion, FVIII therapy was effective, well tolerated, and low titre inhibitors identified did not preclude continued on demand FVIII therapy. Our study has also demonstrated that patients' age and treatment regimen do not affect inhibitor formation. Further studies are necessary to confirm these findings.
Authors:
B Houissa; M L Mliki; S Abdelkafi; M Bouslama; M Zaïer; T Mahjoub; M Kortas; L Ghachem; S Yacoub
Related Documents :
12424426 - Some aspects of hemostasis in capd patients treated with erythropoietin.
18937726 - A case report of plasma exchange, steroids, mycophenolate mofetil and cyclophosphamide ...
11916076 - The utility of activated partial thromboplastin time (aptt) clot waveform analysis in t...
1581216 - Immunological studies in hiv seronegative haemophiliacs: relationships to blood product...
8356526 - Contralateral disease progression after carotid endarterectomy.
329626 - Total and "activated" peripheral blood t lymphocytes in patients with thyroid disorders.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Hämostaseologie     Volume:  23     ISSN:  0720-9355     ISO Abbreviation:  Hamostaseologie     Publication Date:  2003 Aug 
Date Detail:
Created Date:  2003-08-18     Completed Date:  2003-10-23     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8204531     Medline TA:  Hamostaseologie     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  144-8     Citation Subset:  IM    
Affiliation:
Regional Blood Centre, University Hospital Farhat Hached, 4000 Sousse, Tunisia. Batoul.Houissa@fphm.rnu.tn
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Blood Coagulation
Blood Transfusion
Child
Factor VIII / metabolism,  therapeutic use
Hemophilia A / blood,  therapy*
Humans
Middle Aged
Prospective Studies
Tunisia
Chemical
Reg. No./Substance:
9001-27-8/Factor VIII

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Qualitative platelet defect and thrombohaemorrhagic complications in a patient with polycythaemia ve...
Next Document:  Three-dimensional power Doppler ultrasonography for demonstrating associated arteries of hepatocellu...